


Social Vulnerability and the Hispanic Paradox in Cirrhosis Mortality

Praaneet Polineni¹, Alexander Huang¹, Xexin Guo¹, Lihui Zhao¹, Alona Furmanchuk¹, Kiarri Kershaw², Marquita Lewis-Thames², Lisa McElroy³, Dineen Simpson¹, Sanjay Mehrotra⁴, Daniela P. Ladner¹

¹NUTORC, Northwestern University Feinberg School of Medicine, ²PHAM, Northwestern University Feinberg School of Medicine, ³Department of Surgery, Abdominal Transplant, Duke University School of Medicine, ⁴Department of Industrial Engineering and Management Sciences, Northwestern University


Background

- Prior research in a cirrhosis cohort (HealthLNK, 2006-2012) found poor health outcomes for Black and Hispanic patients with cirrhosis, though this does not account for other SDOH^{1,2}.
- Health varies significantly by geography due to societal factors and community level social determinants of health (SDOH)³
- Hispanic patients have been reported to have improved outcomes compared to Non-Hispanic White patients, despite disease and SES





Research Objectives

- Evaluate differences in patient and disease characteristics based on community level SDOH
- Estimate race and ethnicity interactions with SDOH and the effect on cirrhosis mortality and liver transplantation



Methods

Patient Cohort:
 20,010 patients with cirrhosis were identified in a deidentified dataset of patients from 6 centers in the Greater Chicago Metropolitan Area. This data was merged with Illinois Department of Public Health (IDPH) death data and United Network for Organ Sharing (UNOS) transplant data. 5-digit ZIP code data was available for each patient in the dataset.



Social Determinants of Health:
 The CDC Social Vulnerability Index (SVI) is a composite index measure designed initially for disaster management⁴ and applied to predict health outcomes⁵. It is reported as a percentile score (0 to 1 from least vulnerable to most) at the census-tract level and converted 5-digit ZIP code level by population weighted medians.

Competing Risk Survival Analysis:

Fine-Gray sub-distribution hazard model to identify the hazard of all-cause mortality, liver related death, non-liver related death, or liver transplantation with appropriate competing risks or censoring at the end of study. Interaction terms with race and ethnicity, sex, and insurance with SVI.

Table 1. Demographics and Disease Characteristics

Social Vulnerability Index	All	Very Low (0.0-2)	Low (2.1-4)	Moderate (4.1-6)	High (6.1-8)	Very High (8.1-1)	p-value
Number of Patients	20010	2743 (14%)	3732 (19%)	3316 (17%)	4370 (22%)	5849 (29%)	-
Mean (SD) Age - years	2.6 (2.0)	2.7 (2.1)	2.5 (2.0)	2.5 (2.0)	2.7 (2.1)	2.6 (2.0)	<0.01
Mean (SD) age - years	57.1 (11.7)	57.9 (11.9)	57.7 (11.8)	57.0 (11.8)	56.9 (11.8)	56.4 (11.4)	<0.01
Sex							
Female	8516 (43%)	1178 (43%)	1614 (43%)	1401 (42%)	1862 (43%)	2461 (42%)	0.92
Male	9096 (45%)	2023 (74%)	2460 (66%)	1964 (59%)	1730 (40%)	919 (16%)	
Race/Ethnicity							<0.001
White	4416 (22%)	83 (3%)	244 (7%)	385 (12%)	980 (22%)	2724 (47%)	
Black	3264 (16%)	120 (4%)	314 (8%)	355 (11%)	864 (20%)	1611 (28%)	
Hispanic	524 (3%)	82 (3%)	102 (3%)	71 (2%)	173 (4%)	96 (2%)	
Other	2710 (14%)	435 (16%)	612 (16%)	541 (16%)	623 (14%)	499 (9%)	
Insurance							<0.001
Private	10007 (50%)	1287 (47%)	1809 (48%)	1675 (51%)	2207 (51%)	3029 (52%)	
Other	6837 (34%)	1303 (48%)	1600 (42%)	1262 (38%)	1337 (31%)	1335 (23%)	
HCV	3166 (16%)	153 (6%)	323 (9%)	379 (11%)	826 (19%)	1485 (25%)	
Etiology							<0.001
Hep. C	8115 (41%)	850 (31%)	1299 (35%)	1291 (39%)	1868 (43%)	2807 (48%)	
ALD	7409 (37%)	875 (32%)	1217 (33%)	1209 (36%)	1569 (36%)	2539 (43%)	
Biliary	4692 (23%)	784 (29%)	981 (26%)	828 (25%)	974 (22%)	1125 (19%)	
NASH	1645 (8%)	155 (6%)	266 (7%)	238 (7%)	444 (10%)	542 (9%)	
Hep. B	2162 (11%)	416 (15%)	520 (14%)	378 (11%)	435 (10%)	413 (7%)	
Ascites	696 (3%)	81 (3%)	147 (4%)	109 (3%)	167 (4%)	192 (3%)	
Ascites	6847 (34%)	924 (34%)	1347 (36%)	1175 (35%)	1474 (34%)	1954 (33%)	
HE	6947 (35%)	947 (35%)	1338 (36%)	1219 (37%)	1435 (33%)	2008 (34%)	
Var. Bleed	591 (3%)	81 (3%)	118 (3%)	90 (3%)	133 (3%)	169 (3%)	<0.001
SBP	1307 (7%)	193 (7%)	265 (7%)	213 (6%)	273 (6%)	363 (6%)	
HRS	1256 (6%)	180 (7%)	288 (8%)	234 (7%)	268 (6%)	286 (5%)	
HCC	2812 (14%)	434 (16%)	593 (16%)	487 (15%)	626 (14%)	672 (11%)	<0.001
Charlson CI	4.6 (3.5)	4.3 (3.3)	4.5 (3.4)	4.3 (3.4)	4.6 (3.5)	4.9 (3.6)	<0.01
Waitlist	1772 (3.4%)	390 (5.2%)	490 (5.2%)	346 (4.1%)	335 (2.9%)	211 (1.4%)	<0.001
Transplant	885 (1.7%)	193 (2.6%)	261 (2.8%)	172 (2.1%)	164 (1.4%)	95 (0.6%)	<0.001
Death	5663 (11%)	751 (10%)	1051 (11%)	961 (11%)	1197 (10%)	1703 (11%)	0.40

Table 1: Patient demographics and disease characteristics. Significance by Chi-squared, ANOVA p<0.05

Figure 1. Competing Risk Survival Analysis




Figure 1: All-Cause Mortality and Liver Transplantation interactions by Race and Ethnicity and SVI

Table 2. Hazard Ratios of Cirrhosis Outcomes

All-Cause Mortality Covariates	Main Effects Odds Ratios	Model with Interactions Odds Ratios	Liver Transplantation Covariates	Main Effects Odds Ratios	Model with Interactions Odds Ratios
Age SVI	1.03 (1.03-1.04)	1.03 (1.03-1.04)	Age SVI	0.98 (0.98-0.99)	0.98 (0.98-0.99)
Sex	Reference	Reference	Sex	Reference	Reference
Male	1.05 (0.97-1.14)	0.94 (0.78-1.13)	Male	1.24 (1.06-1.46)	1.24 (0.93-1.65)
White	Reference	Reference	White	Reference	Reference
Black	1.47 (1.31-1.64)	1.45 (1.04-2.02)	Black	0.33 (0.24-0.45)	0.66 (0.32-1.36)
Hispanic	0.87 (0.77-0.99)	1.52 (1.07-2.14)	Hispanic	0.63 (0.49-0.81)	0.87 (0.49-1.55)
Asian	0.93 (0.71-1.22)	0.71 (0.35-1.42)	Asian	1.04 (0.65-1.67)	1.59 (0.67-3.76)
Other	1.34 (1.2-1.5)	1.45 (1.15-1.83)	Other	0.61 (0.49-0.77)	0.59 (0.38-0.91)
CMS	Reference	Reference	CMS	Reference	Reference
Private Insurance	1.35 (1.22-1.49)	1.45 (1.1-1.92)	Private Insurance	1.04 (0.89-1.22)	0.91 (0.68-1.22)
Other Insurance	0.95 (0.87-1.04)	0.93 (0.86-1.01)	Other Insurance	0.5 (0.2-0.44)	0.74 (0.4-1.38)
HCV	1.31 (1.18-1.46)	1.31 (1.18-1.45)	HCV	1.26 (1.06-1.49)	1.24 (1.04-1.47)
ETOH	1.36 (1.18-1.56)	1.36 (1.18-1.56)	ETOH	0.71 (0.59-0.85)	0.71 (0.6-0.85)
NASH	1.07 (0.94-1.23)	1.07 (0.94-1.23)	NASH	0.87 (0.66-1.14)	0.87 (0.66-1.15)
HBV	1.57 (1.42-1.72)	1.56 (1.42-1.72)	HBV	0.84 (0.63-1.11)	0.84 (0.63-1.11)
Ascites	1.37 (1.25-1.51)	1.38 (1.25-1.51)	Ascites	1.12 (0.93-1.35)	1.13 (0.94-1.36)
EV	0.55 (0.5-0.6)	0.55 (0.51-0.6)	EV	1.29 (1.07-1.57)	1.29 (1.07-1.57)
VB	0.82 (0.62-1.07)	0.81 (0.62-1.06)	VB	1.67 (1.42-1.98)	1.67 (1.41-1.97)
SBP	0.98 (0.86-1.11)	0.98 (0.87-1.11)	SBP	1.03 (0.73-1.44)	1.03 (0.73-1.45)
HCC	1.45 (1.31-1.57)	1.44 (1.31-1.57)	HCC	2.6 (2.22-3.05)	2.6 (2.22-3.06)
MELD	1.06 (1.05-1.06)	1.06 (1.05-1.06)	MELD	1.06 (1.05-1.07)	1.06 (1.05-1.07)
Charlson	0.98 (0.97-0.99)	0.98 (0.97-0.99)	Charlson	1.06 (1.04-1.09)	1.07 (1.04-1.09)
Asian*SVI	-	1.53 (0.52-4.67)	Asian*SVI	-	0.39 (0.06-2.54)
Black*SVI	-	0.44 (0.27-0.73)	Black*SVI	-	0.33 (0.11-0.99)
Hispanic*SVI	-	0.44 (0.27-0.73)	Hispanic*SVI	-	0.56 (0.23-1.34)

Table 2/3: Hazard ratios for All-Cause Mortality and Liver Transplantation with Interactions

Results

- High SVI has differing effects by race and ethnicity, with Hispanic patients in highly vulnerable areas having lower mortality

Limitations

- This study is retrospective in design and does not identify a direct causal relationship between social determinants and cirrhosis outcomes.
- The SVI measure is limited to the geographic level of data was limited to the 5-digit zip code, within which significant variance of community level SDOH can exist. It is also an index measure not constructed from relevant factors (i.e. food deserts, public spaces).

Conclusions

While increased vulnerability is associated with increased mortality and decreased liver transplantation, this effect is not the same for all patients. Interventions to reduce mortality or improve transplantation among cirrhosis patients needs further research to understand community level barriers to care.

References

- Mauchner NK, Simpson D, Adams K, et al. Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study. *Hepatology*. 2013;57(1):206-216. doi:10.1002/hep.23176
- Adams K, Mauchner NK, Caraco JC, et al. The Hispanic Paradox in Patients With Liver Cirrhosis: Current Evidence From a Large Regional Retrospective Cohort Study. *Transplantation*. 2018;102(12):2531-2538. doi:10.1097/TP.0000000000002732
- Levent T, Polineni A, Thayer R, et al. Disparities in Health Outcomes in Cirrhosis: A Study of the Hispanic Paradox in Cirrhosis. *Journal of Hepatology*. 2011;53(1):100-107. doi:10.1016/j.jhep.2010.08.017
- Polineni P, Guo X, Huang A, et al. A Social Vulnerability Index for Disaster Management. *Journal of Homeland Security and Emergency Management*. 2011; 8(1).
- Kilke AC, Oberlin R, MacIntyre P, et al. Evaluation of Community-Level Vulnerability and Racial Disparities in Living Donor Kidney Transplant. *JAMA Surg*. 2013;108(12):1120-1129. doi:10.1093/surg/108.12.1120